Immune cell score, PD-L1 expression and prognosis in esophageal cancer

Anna Junttila , Juha P. V€ayrynen , Maarit Ahtiainen, Teijo Kuopio, Johanna Mrena, Eero Sihvo and Olli Helminen Department of Surgery, Central Finland Central Hospital, Jyv€askyl€a, Finland; Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland; Department of Education and Research, Central Finland Health Care District, Jyv€askyl€a, Finland; Department of Pathology, Central Finland Central Hospital, Jyv€askyl€a, Finland; Department of Biological and Environmental Science, University of Jyv€askyl€a, Jyv€askyl€a, Finland

[1]  T. Kuopio,et al.  Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer , 2020, British Journal of Cancer.

[2]  J. Ajani,et al.  LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study , 2020 .

[3]  Yuan Luo,et al.  The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy , 2020, Aging.

[4]  Ling Yuan,et al.  The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer , 2020, Frontiers in Oncology.

[5]  T. Zander,et al.  Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma , 2020, Cancer Immunology, Immunotherapy.

[6]  Y. Shim,et al.  High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma , 2019, Scientific Reports.

[7]  Jinming Yu,et al.  A good start of immunotherapy in esophageal cancer , 2019, Cancer medicine.

[8]  B. Melichar,et al.  From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer , 2018, International journal of molecular sciences.

[9]  R. Mehta,et al.  Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy , 2018, OncoTargets and therapy.

[10]  N. Haddad,et al.  Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer. , 2018, The Annals of thoracic surgery.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  L. Fashoyin-Aje,et al.  FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1 , 2018, The oncologist.

[13]  J. Mrena,et al.  Benchmark values for transthoracic esophagectomy are not set as the defined "best possible"-a validation study. , 2018, Journal of thoracic disease.

[14]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[15]  J. Lagergren,et al.  Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study , 2018, BMJ Open.

[16]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[17]  H. Baba,et al.  PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer , 2017, Annals of surgery.

[18]  Yingyong Hou,et al.  Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma , 2017, Scientific Reports.

[19]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[20]  Antoni Ribas,et al.  Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.

[21]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[22]  J. van der Meulen,et al.  Identifying co‐morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score , 2010, The British journal of surgery.

[23]  P. Went,et al.  Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancer. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  V. Rusch,et al.  Worldwide esophageal cancer collaboration. , 2009, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[25]  J. Galon,et al.  Immunoscore assay for the immune classification of solid tumors: Technical aspects, improvements and clinical perspectives. , 2020, Methods in enzymology.